Abstract 2257: The survival impact of XPA and XPC genetic polymorphisms on patients with esophageal cancer

Abstract

Abstract Purpose: To investigate the association of the genetic variants in xeroderma pigmentosum groups A (XPA) and C (XPC) with the overall survival duration of the patients with esophageal cancer. Patients and Methods: A total of 531 patients with a diagnosis of esophageal cancer were enrolled in the study. The genetic variants of XPA in 5’UTR (rs1800975) as well as XPC at exon 15 Lys939Gln (rs2228001) were analyzed with the TaqMan assay from the genomic DNA of peripheral leukocytes. The association of the genotypes and the survival of the patients were analyzed with Cox's multivariate analysis. Results: There was no significant difference of XPA and XPC genotype distribution among patients with various clinical profiles. The overall survival of the patients was significantly influenced by the tumor stage, cell type (squamous cell carcinoma vs. adenocarcinoma) and curative surgical resection (p<0.05 respectively). There was an insignificant unfavorable trend for survival outcome of the patients with XPA 5’UTR (rs1800975) C/T or XPC Lys939Gln (rs2228001) G/G genotypes, compared with those who with other genotypes. Cox's multivariate analysis revealed that accumulation with any one this two unfavorable genotype would associate with a significantly increased risk of death (adjusted HR [95% CI]: 1.27[1.07-1.50]; p=0.005). Compared to those patients without any of these unfavorable genotype, simultaneously having both of these genotype would impose a significantly higher risk of death on the patients after treatment (adjusted HR [95% CI]: 1.86[1.24-2.81]; p=0.003). Conclusion: Our study demonstrates that the hereditary genetic variants in XPA and XPC may play a role for the clinical outcome of the patients with esophageal cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2257. doi:10.1158/1538-7445.AM2011-2257